Larimar Therapeutics, Inc. (NASDAQ:LRMR) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock and pre-funded warrants Announced: US$75M · J.P. Morgan +1 Dealers: J.P. Morgan (co-lead), Guggenheim Securities (co-lead) Use of proceeds: Development of nomlabofusp, working capital and general corporate purposes, including R&D and commercialization expenses | Feb 25, 2026 |
| Public offering of common stock Closed: US$69M raised · US$3.2 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead), William Blair (co-lead) Use of proceeds: Development of nomlabofusp and other pipeline candidates, working capital and general corporate purposes including R&D and pre-commercialization | Jul 31, 2025 |